Nucleic acid molecules and polypeptides against mutans streptococci and their application in the preparation of drugs against mutans streptococci
By developing polypeptides and nucleic acid molecules that are anti-State mutans, the problem that the prior art cannot effectively inhibit Streptococcus mutans is solved, and efficient antibacterial effects are achieved, providing new methods for the prevention and treatment of caries.
Patent Information
- Application Number
- CN202410623662.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-20
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-05-20
AI Technical Summary
The existing caries prevention and treatment methods cannot effectively solve the problems of dental tissue damage and bacterial drug-dependent properties. Traditional methods cannot fundamentally inhibit the growth of Streptococcus mutans and affect the oral microecological balance.
A polypeptide against Streptococcus mutans and corresponding nucleic acid molecules were developed. Monoclonal antibodies were obtained through immunization of mice, fusion and subclonal screening. The encoded polypeptide can inhibit the proliferation of Streptococcus and is used to prepare anti-State mutans drugs. .
This polypeptide can effectively inhibit the growth of streptococci, with an antibacterial efficiency of 50% or more, providing a new method for preventing and treating caries.
Smart Images

Figure CN118638220B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to a nucleic acid molecule and a polypeptide for resisting mutans streptococcus and the application of the nucleic acid molecule and polypeptide for resisting mutans streptococcus in preparing a medicine. Background Art
[0002] Dental caries is a chronic oral infectious disease characterized by an imbalance of oral microecology caused by multiple factors, mainly bacterial factors. It is the most common bacterial disease in humans1.2, with high morbidity and low treatment rate, which seriously endangers oral and systemic health. Strengthening and improving the standardized treatment of dental caries is a key issue facing dental caries management for the entire population and throughout the life cycle. At present, the focus of dental caries prevention is on the removal of dental plaque, which is composed of a large number of symbiotic microorganisms. Therefore, the concept of "removing or killing all" plaque microorganisms creates an open and non-competitive environment for pathogenic microorganisms. Traditional methods of preventing or treating dental caries cannot fundamentally solve problems such as tooth tissue damage and bacterial drug dependence. Microecological preparations and antimicrobial peptides have emerged as the times require. They inhibit oral pathogens to achieve the purpose of regulating the balance of oral microecology, which is a new method for preventing and treating dental caries.
[0003] Mutans Streptococcus is a resident flora in the oral cavity and plays an important role in the early stage of dental caries. Therefore, research on mutans Streptococcus plays a key role in the prevention and treatment of dental caries. Therefore, it is necessary to develop a drug against mutans Streptococcus. Summary of the invention
[0004] In order to solve the technical problem, the present invention provides nucleic acid molecules and polypeptides against mutans streptococci and their use in preparing drugs against mutans streptococci. The polypeptides against mutans streptococci can inhibit the proliferation of streptococci and thus can be used to prepare drugs against mutans streptococci.
[0005] The present invention is implemented by the following technical solutions:
[0006] In a first aspect of the present invention, a polypeptide for resisting Streptococcus mutans is provided, wherein the amino acid sequence of the polypeptide for resisting Streptococcus mutans is shown in SEQ ID NO.6.
[0007] Furthermore, the polypeptide also includes:
[0008] An antibody with the same function obtained by replacing, deleting and / or adding one or more amino acids to the amino acid sequence of the polypeptide;
[0009] Or comprises an amino acid sequence having at least 80% homology with said plurality.
[0010] In the second aspect of the present invention, a nucleic acid molecule encoding the polypeptide against mutans Streptococcus is provided.
[0011] Furthermore, the nucleotide sequence of the anti-Streptococcus mutans nucleic acid molecule is shown in SEQ ID NO:7.
[0012] Furthermore, the nucleic acid molecule against mutans streptococci also includes: at least one of the nucleic acid molecules is modified, and the modification includes at least one of phosphorylation, methylation, amination, sulfhydrylation, replacement of oxygen with sulfur, replacement of oxygen with selenium, or isotopization.
[0013] Furthermore, the nucleic acid molecule against Streptococcus mutans also includes: at least one of the nucleic acid molecules is connected to a substance for marking or treatment; the substance for marking or treatment includes: at least one of a fluorescent marker, a radioactive substance, a therapeutic substance, biotin, digoxin, a nanoluminescent material and a small peptide.
[0014] In the third aspect of the present invention, an expression vector comprising the nucleic acid is provided, wherein the expression vector is capable of expressing the nucleic acid in a prokaryotic or eukaryotic host cell.
[0015] In the fourth aspect of the present invention, an engineered bacterium or eukaryotic host cell comprising the expression vector is provided.
[0016] In the fifth aspect of the present invention, there is provided use of the polypeptide or the nucleic acid molecule or the expression vector or the engineered bacteria or eukaryotic host cell in the preparation of a drug against Streptococcus mutans.
[0017] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:
[0018] The invention provides nucleic acid molecules and polypeptides for resisting mutans streptococci and their use in preparing drugs for resisting mutans streptococci. The polypeptides can inhibit the proliferation of streptococci, and compared with a control group, the antibacterial efficiency reaches 50% or more. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0020] Figure 1 This is a schematic diagram of the antibody encoding gene structure (including the 5' and 3' non-coding regions);
[0021] Figure 2 The electrophoresis diagram of VH and VL PCR amplification, in which VL1-VL2 and VH1-VH2 fragments were amplified using different primer systems; MW: DL2000;
[0022] Figure 3 The electrophoresis diagram of colony PCR is shown in Figure 2. MW: DL10000 and DL2000. The positive clones identified were selected for sequencing analysis.
[0023] Figure 4 The total protein was extracted from the antigen preparation in Example 1 and the SDS-PAGE identification results were obtained. DETAILED DESCRIPTION
[0024] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.
[0025] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.
[0026] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.
[0027] The overall idea of the present invention is as follows:
[0028] Through immunization of mice, fusion and subclone screening, a monoclonal antibody KLH336 was obtained.
[0029] The antibody comprises a heavy chain variable region and a light chain variable region:
[0030] The heavy chain variable region has three complementary determining regions of the amino acid sequences shown in SEQ ID NO: 1-SEQ ID NO: 3; GFTSFDFY (SEQ ID NO: 1); SKNKFNGYTT (SEQ ID NO: 2); ARGNWDVDFDY (SEQ ID NO: 3).
[0031] Further, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 4 (EVKLVESGGGLVQPGGSLRLSCATSGFTFSDFYMEWVRQPPGKGLEWIAASKNKFNGY TTVYSASVKGRFIVSRDTSQSILYLQMNALRAEDTAVYYCARGNWDVDFDYWGQGTTLT VSS);
[0032] The amino acid sequence of the light chain variable region is shown in SEQ ID NO: 5:
[0033] (DVLMTQTPLSLPVSLGDQASISCRSSQNIVHSNGDTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK); after removing the mouse fixed region, the light chain antibody variable region sequence is as shown in SEQ ID NO: 8, and the sequence is QNIVHSNGDTYKVSFQGSHVPWT;
[0034] Further analysis revealed that:
[0035] The mouse fixed region is removed from the heavy chain variable region, and the amino acid sequence is shown in SEQ ID NO: 6, which is GFTSFDFYSKNKFNGYTTARGNWDVDFDY. Experiments have shown that the polypeptide shown in the amino acid sequence of SEQ ID NO: 6 (called the anti-streptococcus mutans polypeptide) can inhibit the proliferation of streptococci, and thus can be used to prepare anti-streptococcus mutans drugs.
[0036] The nucleic acid molecule encoding the polypeptide against Streptococcus mutans is shown in SEQ ID NO: 7;
[0037] GGGTTCACCTTCAGTGATTTCTACAGTAAAAAACAAATTTAATGGTTATACAACAGCAAGAGGCAACTGGGACGTAGACTTTGACTAC.
[0038] The antibodies of the present application, their preparation methods and application effects are described in detail below in conjunction with the examples and experimental data. Specific experimental conditions and methods not specified in the following examples are usually in accordance with conventional conditions such as those described in J. Sambrook et al., ed., Molecular Cloning Experiment Guide (3rd edition), Science Press, 1992; DL Spector et al., Cell Experiment Guide, Science Press, 2001, or the conditions recommended by the manufacturer.
[0039] The bacteria used in this experiment were the international reference strain S. mutans Ingbritt (serotype C), which was purified in the selective culture medium for Streptococcus mutans MSB. A single typical colony was picked and cultured in TSB at 37 degrees with microaerobic culture (95% N2, 5% CO2) for 24 hours. The total protein was extracted and identified by SDS-PAGE.
[0040] Example 1. Obtaining polypeptides and nucleic acid molecules against Streptococcus mutans
[0041] 1. Antigen preparation
[0042] The bacteria used in this experiment were the international reference strain S. mutans Ingbritt (serotype C), which was purified in the selective culture medium for Streptococcus mutans MSB. A single typical colony was picked and cultured in TSB at 37 degrees for 24 hours (95% N2, 5% CO2). The total protein was extracted and identified by SDS-PAGE (the results are shown in Figure 2). Figure 4 shown).
[0043] 2. Five mice were immunized with the antigen for four times, as shown in Table 1.
[0044] Table 1
[0045]
[0046] 3. Fusion and subclone screening
[0047] Select 1-2 mice with good serum immunization results and good verification results, take out the spleen for cell fusion, screen with HAT medium to obtain positive hybridoma cells, subclone the positive hybridoma cells by limiting dilution method to obtain monoclonal cell lines, perform 2-3 rounds of indirect ELISA screening during each subclone, and establish the strain after obtaining the positive monoclonal cell lines that meet the requirements.
[0048] 4. Single cell line sequencing
[0049] Total RNA was extracted from hybridoma cell lines and reverse transcription PCR was performed to amplify cDNA. The variable region sequences of the antibodies were amplified by PCR using subtype-specific primers, followed by RT-PCR modified by SMART (Switching Mechanism at the 5' End of RNA Transcripts) technology. This technology is based on the intrinsic properties of Moloney mouse leukemia virus (MMLV) reverse transcriptase and the use of a custom sequence template-switch oligo upstream primer containing 3 riboguanines (rGrGrG) at its 3' end. In order to amplify the variable regions of the antibodies, RT-PCR reverse primers were designed targeting highly conserved sequences in the constant regions of mouse antibody kappa, lambda and IgG heavy chains (Tables 2 and 3).
[0050] Table 2 - Mouse IgG reverse transcription primers
[0051]
[0052] Table 3 - Mouse IgG reverse transcription primers
[0053]
[0054] 5. The RT-PCR amplification process of the antibody variable region is as follows:
[0055] Step 1. After the primers in Table 2 specifically bind to the highly conserved constant region on the hybridoma RNA, MMLV reverse transcriptase initiates polymerization.
[0056] Step 2: After the MMLV reverse transcriptase reaches the 5' end of the RNA template during first strand synthesis, it adds a few nucleotides, usually deoxycytidine, to the 3' end of the cDNA transcript. These added bases allow for binding of the template conversion oligonucleotide after annealing.
[0057] Step 3. When base pairing occurs between the 3' riboguanine of the template switching oligonucleotide and the deoxycytosine of the cDNA, the MMLV reverse transcriptase switches the template and continues polymerization. Note: At this time, the template switching oligonucleotide is used as the template for polymerization, not the hybridoma RNA.
[0058] Step 4: MMLV reverse transcriptase initiates polymerization until the 5' end of the template-converted oligonucleotide is reached, resulting in a single-stranded cDNA molecule containing the starting universal sequence.
[0059] Step 5. The final result is a single-stranded cDNA molecule containing the starting universal sequence.
[0060] Step 6: Use the single-stranded cDNA as a template to synthesize double-stranded cDNA.
[0061] Step 7. Perform PCR amplification using the added universal sequence. The forward PCR primer (Table 3) has the same sequence as the template switching oligonucleotide; the reverse PCR primer (Table 3) is specific to the constant region (the second highly conserved sequence) of each chain and is nested in the cDNA sequence to improve amplification specificity.
[0062] The products were subcloned into T vectors and sequenced. Figure 1 shown.
[0063] 6. Antibody subtype identification
[0064] The culture supernatant was added to the ELISA plate coated with Anti-mouse IgGAb, and the antibody subtype was analyzed by using different HRP-labeled anti-mouse subtype secondary antibodies. The results are shown in Table 4:
[0065] Table 4 Antibody subtype determination results
[0066] 1-KLH-336 2-KLH-336 3-KLH-336 4-KLH-336 IgG1 0.10 2.21 0.91 2.04 IgG2a 2.43 0.14 0.10 0.10 IgG2b 0.08 0.19 0.09 0.09 IgG2c 0.11 0.08 0.08 0.08 IgG3 0.10 0.07 0.08 0.08
[0067] 7. Sequencing methods
[0068] Total RNA was extracted from the hybridoma cell line, and total cDNA was amplified by RT-PCR using oligo-dT as primer. Using cDNA as template, VH or VL variable region fragments were amplified by nested-PCR using forward degenerate primers (designed according to V or L gene) and reverse constant region specific primers (the primer sequences used are shown in the table below) (see Figure 2 ). The PCR product was connected to the T vector and colony PCR was performed after transformation (see Figure 3 ) and selected positive clones for sequencing analysis.
[0069] Table 5 Primers for light chain variable region fragments
[0070] name Sequence (5'-3') Primer 1 GGTGATAICGTGAT(A / G)AC(C / A)CA(G / A)GATGAACTCTC(SEQ ID NO: 17) Primer 2 GGTGATATC(A / T)TG(A / C)TGACCCAA(A / T)CTCCACTCTC(SEQ ID NO: 18) Primer 3 GGTGATATCGT(G / T)CTCAC(C / T)CAA / G)TCTCCAGCAAT(SEQ ID NO: 19)
[0071] Table 6 Primers for heavy chain variable region and light chain variable region fragments
[0072] name Sequence (5'-3') Primer 1 GACGTGAAGCTGCAGGAGTCAGGAOCTAGCCTGGTG (SEQ ID NO: 20) Primer 2 AGGT(C / G)(A / C)AACTGCAG(C / G)AGTC(A / T)GG(SEQ ID NO: 21) Primer 3 AGGT(C / G)(AC)AGCTGCAG(C / G)AGTC(A / T)GG(SEQ ID NO: 22) Primer 4 AGGT(C / G)CAGCTGCAG(C / G)AGTC(A / T)GG(SEQ ID NO: 23)
[0073] The sequencing result of the antibody heavy chain is shown in SEQ ID NO: 4. The sequencing result of the antibody light chain is shown in SEQ ID NO: 5. 6. Obtaining the polypeptide against Streptococcus mutans
[0074] The amino acid sequence SEQ ID NO: 6 can be directly synthesized.
[0075] GFTFSDFYSKNKFNGYTTARGNWDVDFDY, to obtain peptides against Streptococcus mutans.
[0076] In other embodiments, a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO: 7 can be used to construct an expression plasmid for expression to obtain a polypeptide against Streptococcus mutans.
[0077] Example 2: Study on the actual effect of resistance
[0078] 1. Experimental strain: The strain is Streptococcus mutans 8148
[0079] 2. Preparation of culture medium: Use MRS broth, main ingredients (g / L): peptone 10g, beef powder 5g, glucose 20g, Tween 80 1ml, dipotassium hydrogen phosphate 2g, sodium acetate 5g, yeast powder 4g, magnesium sulfate 0.2g, magnesium sulfate 0.05g, tri-eucalyptus citrate 2g. Take 48g MRS broth and add 1000ml distilled water for autoclave sterilization.
[0080] 3. Experimental method: Take 15 50ml centrifuge tubes, add 10ml MRS liquid culture medium to every tube and inoculate 100ul mutans streptococcus strain. Be divided into 2 groups (PBS group, experimental group), the experimental group adds 50ug, 200ug, 500ug, 1000ug, 2000ug of the polypeptide of the anti-mutans streptococcus prepared in Example 1 respectively, place 37 ℃, 120r / min shaking table overnight culture, measure the absorbance value under the 600nm wavelength of each centrifuge tube thalline the next day.
[0081] Table 7 Absorbance detection data
[0082] Sample volume / ul 10 20 50 100 200 PBS group 0.824 0.810 0.835 0.841 0.813 Anti-Streptococcus mutans peptide 0.687 0.632 0.502 0.421 0.409
[0083] As shown in Table 7, as the amount of antibody added increases, the concentration OD value of Streptococcus 8148 decreases, which can prove that the anti-Streptococcus mutans polypeptide of the present invention can effectively inhibit the growth of Streptococcus. Compared with the control group, the antibacterial efficiency is 50% or more.
[0084] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.
[0085] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0086] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A polypeptide against Streptococcus mutans, characterized in that The amino acid sequence of the polypeptide against Streptococcus mutans is shown in SEQ ID NO.
6.
2. A nucleic acid molecule encoding an anti-Streptococcus mutans polypeptide according to claim 1.
3. The nucleic acid molecule of the anti-Streptococcus mutans according to claim 2, characterized in that The nucleotide sequence of the nucleic acid molecule against Streptococcus mutans is shown in SEQ ID NO:
7.
4. An expression vector comprising the nucleic acid molecule according to any one of claims 2 to 3, characterized in that: The expression vector is capable of expressing the nucleic acid molecule in a prokaryotic or eukaryotic host cell.
5. An engineered bacterium comprising the expression vector according to claim 4.
6. Use of the polypeptide according to claim 1, the nucleic acid molecule according to any one of claims 2 to 3, the expression vector according to claim 4, or the engineered bacteria according to claim 5 in the preparation of a drug against Streptococcus mutans.
Citation Information
Patent Citations
Antivariant streptococcus polypeptide and use thereof and preparation method
CN101423554A
Deformed streptococcus adherence resisting polypeptide mixture
CN1350002A
Vaccine, antibodies & antibody-containing compositions for inhibiting human dental caries induced by streptococcus mutans
US5240704A
